Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
NCT ID: NCT03812523
Last Updated: 2019-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2019-06-30
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NR in Chemo-induced Peripheral Neuropathy
NCT03642990
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
NCT02808624
Lidocaine for Oxaliplatin-induced Neuropathy
NCT03254394
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
NCT03909464
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
NCT00754767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Duloxetine 60 mg qd
Duloxetine 60 mg qd
60 mg tablet Taken by mouth, Once Daily for 180 Days
Intervention
Lorcaserin 10 mg bid
Lorcaserin
10 mg tablet Taken by mouth Twice Daily for 180 Days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duloxetine 60 mg qd
60 mg tablet Taken by mouth, Once Daily for 180 Days
Lorcaserin
10 mg tablet Taken by mouth Twice Daily for 180 Days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has agreed to receive treatment at Cancer Treatment Centers of America, Southeastern Regional Medical Center.
* Subject is Male or Female
* Subject is 18 years of age or older.
* Subject is a patient who reports neurotoxicity symptom grade 2 or more according CTCAE criteria to his or her medical oncologist following one or more cycles of oxaliplatin-based chemotherapy treatment.
* Subject is a patient who is capable and accepting of completing study questionnaires at each data collection point.
* Subject has adequate English fluency for completion of data collection. The surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
* Subject must have the ability to understand and the willingness to sign a written informed consent
* Subject must be willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria
* Subjects with pre-existing comorbidities, such as: diabetes, uremia, significant peripheral vascular disease, HIV, or progressive or degenerative neurologic disorders (e.g., multiple sclerosis, B12 deficiency); cardiovascular valve disease, history of cardiovascular event,
* Subjects with a history of lumbosacral laminectomy or radiculopathy;
* Subjects who have been prescribed and taken gabapentin, pregabalin, or duloxetine currently or within the last 1 months)
* Subjects who have established or suspected family history of inherited neuropathy.
* Subjects unable to swallow indicated medication
* Subjects in general with a medical condition, laboratory finding, or physical exam finding that precludes participation
* Subject weight of ≥350 lbs.
* Subjects who currently use disallowed concomitant medications
* Subjects with any form of cardiac implants
* Subjects who report recent febrile illness that precludes or delays participation
* Subjects with pregnancy or lactation
* Subjects with known allergic reactions to components of the study product(s)
* Subjects receiving treatment with another investigational drug or other intervention
* Subjects with a history of or current tobacco or illegal substance use
* Subjects exhibiting significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Southeastern Regional Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Treatment Centers of America - Atlanta
Newnan, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SA2018005 LVD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.